We are live on ! Find out more
XRTX

XORTX Therapeutics
XRTX

7 hedge funds and large institutions have $41.1K invested in XORTX Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

41% more capital invested

Capital invested by funds: $29.2K → $41.1K (+$11.9K)

40% more funds holding

Funds holding: 5 → 7 (+2)

0.32% more ownership

Funds ownership: 0.53% → 0.85% (+0.32%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
7
Holders Change
+2
Holders Change %
+40%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$32.1K
2
National Bank of Canada
National Bank of Canada
Quebec, Canada
+$5.89K
3
TRCT
Tower Research Capital (TRC)
New York
+$145

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$23.3K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$950

XRTX Hedge Fund Activity: Q3 2024 in Review

7 of the 6,979 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q3 2024, worth a combined $41.1K — up 41% from $29.2K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new XRTX positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $32.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $23.3K sold.

  • 7 institutional investors held XORTX Therapeutics (XRTX) as of Q3 2024, up from 5 in Q2 2024.
  • Funds reported $41.1K of XORTX Therapeutics stock for Q3 2024, up 41% quarter-over-quarter.
  • 3 funds opened new XORTX Therapeutics positions in Q3 2024 and 1 closed out, a net change of +2 holders.
  • The largest XORTX Therapeutics buyer in Q3 2024 was UBS Group, an estimated $32.1K added.
  • The largest XORTX Therapeutics seller in Q3 2024 was Citadel Advisors, an estimated $23.3K sold.

Based on aggregated 13F filings for Q3 2024.